Interaction Checker

Wechselwirkungen von Trastuzumab

Trastuzumab (Herceptin, Ogivri, Kanjinti) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 75 dokumentierte Wechselwirkungen: 4 schwerwiegende, 48 mittelschwere, 23 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (4)

  • CyclophosphamidImmunsuppressivumSchwerwiegend

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DoxorubicinSchwerwiegend

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • ItraconazolAzol-AntimykotikumSchwerwiegend

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

  • PaclitaxelSchwerwiegend

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Mittelschwere Wechselwirkungen (48)

  • AclidiniumbromidAnticholinergikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • AdrenalinSympathomimetikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • AminophyllinMethylxanthinMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • ArformoterolBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Articain und AdrenalinLokalanästhetikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Azelastin und FluticasonAntihistaminikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • BudesonidKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Bupivacain und AdrenalinLokalanästhetikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • CarboplatinMittelschwer

    In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DeflazacortKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DesonidKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DiphenhydraminAntihistaminikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DocetaxelMittelschwer

    In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • FludrocortisonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • FormoterolBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • HalobetasolKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • IpratropiumbromidAnticholinergikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Ipratropiumbromid und SalbutamolAnticholinergikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • IsoprenalinBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • LevosalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Lidocain und AdrenalinLokalanästhetikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylprednisolonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • MirabegronBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • MometasonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Prilocain und AdrenalinLokalanästhetikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • SalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • SalmeterolBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • TerbutalinBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • TheophyllinMethylxanthinMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • TiotropiumbromidAnticholinergikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • TriamcinolonKortikosteroidMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • UmeclidiniumbromidAnticholinergikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Umeclidiniumbromid und VilanterolAnticholinergikumMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • VibegronBeta-Adrenozeptor-AgonistMittelschwer

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (23)

  • AzelastinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Brompheniramin, Pseudoephedrin und DextromethorphanAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbinoxaminAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • CetirizinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorphenaminAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • ClemastinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • CyproheptadinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DesloratadinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DexchlorpheniraminAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DimenhydrinatAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DoxylaminAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Doxylamin und PyridoxinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • FexofenadinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und ChlorphenaminOpioidGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • HydroxyzinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • LevocetirizinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • LoratadinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • MeclozinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • OlopatadinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • PalbociclibCYP3A4-HemmerGeringfügig

    Grade ≥3 neutropenia was reported in 61% of patients receiving IBRANCE in combination with trastuzumab, with or without pertuzumab, and endocrine therapy. (Fachinformation zu Palbociclib, Warnhinweise und Vorsichtsmaßnahmen)

  • PromethazinAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und CodeinOpioidGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und DextromethorphanAntihistaminikumGeringfügig

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Trastuzumab gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.